Objective. To design a precision medicine approach aimed at exploiting significant patterns in data, in order to produce venous thromboembolism (VTE) risk predictors for cancer outpatients that might be of advantage over the currently recommended model (Khorana score). Design: Multiple kernel learning (MKL) based on support vector machines and random optimization (RO) models were used to produce VTE risk predictors (referred to as machine learning [ML]-RO) yielding the best classification performance over a training (3-fold cross-validation) and testing set. Results. Attributes of the patient data set (n = 1179) were clustered into 9 groups according to clinical significance. Our analysis produced 6 ML-RO models in the training set, which yielded better likelihood ratios (LRs) than baseline models. Of interest, the most significant LRs were observed in 2 ML-RO approaches not including the Khorana score (ML-RO-2: positive likelihood ratio [+LR] = 1.68, negative likelihood ratio [-LR] = 0.24; ML-RO-3: +LR = 1.64, -LR = 0.37). The enhanced performance of ML-RO approaches over the Khorana score was further confirmed by the analysis of the areas under the Precision-Recall curve (AUCPR), and the approaches were superior in the ML-RO approaches (best performances: ML-RO-2: AUCPR = 0.212; ML-RO-3-K: AUCPR = 0.146) compared with the Khorana score (AUCPR = 0.096). Of interest, the best-fitting model was ML-RO-2, in which blood lipids and body mass index/ performance status retained the strongest weights, with a weaker association with tumor site/stage and drugs. Conclusions. Although the monocentric validation of the presented predictors might represent a limitation, these results demonstrate that a model based on MKL and RO may represent a novel methodological approach to derive VTE risk classifiers. Moreover, this study highlights the advantages of optimizing the relative importance of groups of clinical attributes in the selection of VTE risk predictors.
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A major challenge that oncologists are facing is the risk assessment of chemotherapy-associated venous thromboembolism (VTE), which may result in treatment delays with detrimental effects on disease outcome. 1 Nonetheless, all current consensus guidelines do not recommend routine prophylaxis for the primary prevention of VTE in chemotherapytreated cancer outpatients, 2,3 although ''it may be considered for selected high-risk patients.'' 3 Thus, selecting patients for prophylactic anticoagulation is perceived as a growing necessity in cancer patient management, fostering the demand for risk assessment models.
However, predicting VTE risk for cancer patients is a compelling challenge where precision medicine can play a crucial role, as VTE risk differs not only among patients but also in the same patient over the course of the natural history of cancer. [4] [5] [6] In 2008, Khorana and colleagues 7 proposed a VTE risk assessment model that uses a combination of routinely available variables. To date, the Khorana score (KS) is the sole model available for VTE prediction in chemotherapy-treated cancer outpatients. Hence, it has been proposed in recent guidance statements. 8 Nonetheless, although it was validated by some independent groups, 9,10 others did not validate it, [11] [12] [13] as the KS fails to classify .50% of patients (intermediate risk), in whom clinical decision making remains challenging. Expanded risk scoring models, including biomarkers 9 or anticancer drugs, 14 were proposed to implement KS, but VTE risk prediction for chemotherapy-treated cancer outpatients remains suboptimal.
A solid base on which to build a precision medicine tool in oncology is represented by machine learning (ML), [15] [16] [17] [18] [19] which can derive patterns in clinical and biochemical knowledge 20 and has been previously applied to learn VTE risk predictors in the general population. 21 Therefore, the aim of the present study was to analyze the performance of a multiple kernel machine learning (MKL) model that combines support vector machines (SVMs), 22, 23 and random optimization (RO) 24 to produce VTE risk predictors in a population of consecutive ambulatory cancer patients representative of a general practice cohort. These predictors exploit significant patterns in data-connoting causality between individual features and VTE-and can be used in the development of a clinical decision support system for VTE risk stratification prior to chemotherapy start.
METHODS

Learning VTE Risk Predictors within a Precision Medicine Approach
To deal with heterogeneity of clinical attributes, our methodology is based on an MKL model 25, 26 that combines SVM 22 to learn classifiers and RO 24 to devise relative importance of different groups of clinical attributes in final predictions.
Based on MKL, our VTE risk predictors are binary classifiers that have to determine whether patients x will have a high risk of developing a VTE event in the future (y = 1) or not (y = -1). In equation 1, sgn(z) is the sign function that is 1 if z . 0 and -1 if z \ 0, patients x are represented with their clinical attributesx5 x 1 , . . . ,x n ð Þdivided in groups x5g 1 ,g 2 , . . . ,g N ½ , w i ! are the decision hyperplanes for each group of attributes, and a i are the relative weights of the groups of attributesg i . Using a i , these VTE risk predictors take into account the heterogeneity of clinical attributes. VTE risk predictors are learned with an n-fold cross-validation on a training set that allows derivation of parameters a i with RO by optimizing the F-measure of classifiers f(x) whose decision hyperplanes w i ! are learned with SVM. The F-measure is defined as
that is a harmonic mean of positive predictive value (PPV) and sensitivity, which are called Precision (P) and Recall (R) in ML. As RO depends on the initial seed, we run the learning multiple times. Predictors are then sorted according to their decreasing F-measure on the training set.
To assess their validity, learned VTE risk predictors are evaluated on a separated testing set.
Our method to find the best VTE risk predictors has 2 major benefits: first, it selects the best predictors on training data; second, it determines relative weights a i among groups of clinical attributes. These weights give useful insights on how predictors take their decisions.
Patient Data Set for VTE Risk Assessment
The patient data set was attained by joint efforts between the PTV Bio.Ca.Re. (Policlinico Tor Vergata Biospecimen Cancer Repository) and the BioBIM (InterInstitutional Multidisciplinary Biobank, IRCCS San Raffaele Pisana) and consisted of 1179 consecutive ambulatory cancer patients with primary or relapsing/recurrent solid cancers who were prospectively followed under the institutional ethics approval in accordance with the principles embodied in the Declaration of Helsinki. All patients were required to be at the start of a new chemotherapy regimen, and no patient received thromboprophylaxis. Eligibility criteria are detailed in Supplementary Table S1 . Clinical characteristics and laboratory attributes of patients are summarized in Supplementary Table S2 .
All patients received specific anticancer treatment, with or without supportive care agents, according to guidelines for cancer treatment by site. All patients were regularly seen at the medical oncology ward of the Department of Systems Medicine, PTV, at time of scheduled chemotherapy visits or at the occurrence of clinically suspected VTE. Deep venous thrombosis (DVT) or pulmonary embolism (PE) were diagnosed as previously reported. 6 During a 1-year median follow-up, VTE occurred in 8% (29 PE and 65 DVT) of patients (median time to event = 3 months). Thirty-four (2.9%) patients had a previous history of VTE, and 5 (0.4%) had concurrent DVT on the first week of treatment. Forty-one of 94 events were incidentally diagnosed (16 PE and 25 DVT) at time of restaging. Competing mortality at 6 months was approximately 2%, and 25 patients without VTE died of their disease during this time frame.
Experimental Settings
To test our methodology and default methods, the patient data set was used as follows: 1) clinical attributes were clustered in 9 groups; 2) the patient data set was randomly divided in training and testing set; 3) values x of continuous clinical attributes c were rescaled with functions f x ð Þ5 À0:51
where m c and M c are the minimal and the maximal values of c in the training set; and 4) missing clinical attribute values were treated according to the (predictive) value imputation method by replacing missing values with the average of the attribute observed in the training set. 27 Group clustering was performed according to the clinical significance of the attributes included in the patient data set. In particular, demographic variables and tumor site/stage were individually considered given their importance as risk factors for VTE. 5, 28 Hematological attributes, including blood cell counts 8, 29 and neutrophil and platelet-to-lymphocytes ratios, 30 were grouped together. Similarly, individual attributes concerning fasting blood lipids, glycemic indexes, and liver and kidney function were clustered within 3 individual groups. Body mass index (BMI) and Eastern Cooperative Oncology Group Performance Status (ECOG-PS) were considered within the same group. Supportive and anticancer drugs were collectively considered under the definition of ''drugs.'' Details on groups of clinical attributes are reported in Figure 1 .
To learn our VTE risk predictors, the patient data set was randomly divided into 2 needed sets:
1. Training set: 70% of the cases were used to learn risk predictors with SVM and to optimize the parameters a i with RO with a 3-fold cross-validation (see equation 1) 2. Testing set: 30% of the cases were used to test the learned risk predictors
We performed 5 different learning sessions on the training set with 5 different RO initializations ( Table  1 ). The final performance was then evaluated on the separated testing set (see Table 2 ). Experiments were performed including or not the KS. Supplementary Table S2 . BMI, body mass index; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; eGFR, estimated glomerular filtration rate; NLR, neutrophil/lymphocyte ratio; PLR, platelet/lymphocyte ratio.
Statistical Analysis
Machine learning used for the primary analysis was run on KELP. 31 Bayesian analysis was performed, and positive (+LR) and negative (-LR) likelihood ratios were used to estimate the probability of having or not VTE, using a free web-based application (http://statpages.org/). Time to event was calculated from the enrolment date until VTE or the most recent follow-up visit. VTE-free survival Note: ML-RO models are ranked according to F-measure. PPV = positive predictive value; -LR = negative likelihood ratio; CI = confidence interval; +LR = positive likelihood ratio; ML = machine learning; RO =random optimization. a. Patients with brain cancer (n = 5) were excluded from the analysis; Khorana score not applicable. Note. ML-RO models are ranked according to F-measure on the training set (see Table 1 ). PPV = positive predictive value; -LR = negative likelihood ratio; CI = confidence interval; +LR = positive likelihood ratio; ML = machine learning; RO = random optimization. a. Patients with brain cancer (n = 2) were excluded from the analysis; Khorana score not applicable.
curves were calculated by the Kaplan-Meier method, and the significance level was assessed by log-rank test using a computer software package (Statistica 8.0, StatSoft Inc., Tulsa, OK). For administrative censoring, VTE was considered to be an event if occurring during chemotherapy administration but not subsequent follow-up. This study had no external funding source.
RESULTS
The weights a i of groups of clinical attributes for the ROs models are reported in Table 3 . Tables 1  and 2 summarize the results achieved using the risk predictors selected on the training and testing sets out of 5 runs obtained with RO using (ML-RO-1-K through ML-RO-5-K) or not (ML-RO-1 through ML-RO-5) the KS and 4 different baseline models: 1) Khorana k ! 3: pure KS with cutoff at 3; 8 2) Khorana-ML: an SVM VTE event predictor trained with a polynomial kernel of degree 2 that uses only the KS as feature; 3) basic-ML-K; and 4) basic-ML. The 2 latter predictors are SVM VTE predictors in which each group of clinical attributes has the same weight: Basic-ML-K uses KS and Basic-ML does not use it.
As shown in Table 1 , an ML approach with RO was capable of improving VTE risk prediction compared with Khorana k ! 3 or Khorana-ML as demonstrated by a substantial improvement of the F-measure, translating in comparable precision (or PPV) and considerably higher recall (or sensitivity) values.
To better characterize the performance of the proposed method, +LR and -LR were calculated for all ML-RO models in comparison with Khorana k ! 3 or Khorana-ML. As shown in Table 1 , the LRs achieved using the KS (with or without an ML approach) were not significant in terms of VTE risk prediction. Conversely, all ML-RO models including the KS resulted in an overall improvement of the LRs for VTE risk prediction, whereas the ML-RO approaches, not including the KS, yielded significant results in ML-RO-1 (P \ 0.0001), ML-RO-3 (P = 0.015), and ML-RO-4 (P = 0.007) but not in the other ML-ROs (Table 1) .
When the algorithm was applied to the testing set, among all ML models including the KS, the best-fitting model was represented by ML-RO-3-K (+LR = 1.52, -LR = 0.55; P = 0.017; Table 2 ). On the other hand, the ML approach not including the KS yielded the best results in ML-RO-2 (ML-RO-2: +LR = 1.68, -LR = 0.24; P \ 0.0001).
Finally, the improvement of the ML approach with RO was confirmed by plotting recall versus precision for the different systems on the test. Figure 2 reports the recall versus precision curves for the basic and the 2 best-fitting models. As shown, ML-RO-2 was the best predictor with an area under the precision-recall curve of 0.212.
As the probability of VTE occurrence during chemotherapy is also a function of time (being maximal during the first 6 months of treatment), 5,6 we finally Figure 3 reports the Kaplan-Meier curves for patients in the testing set stratified on the basis of Khorana k ! 3 and the 2 best-fitting ML-RO models. As shown, despite a high precision, the KS used at a cutoff !3 points, as currently recommended, 8 resulted in a 6-month VTE-free survival rate not significantly different from that of low-risk patients (Figure 2A ). On the other hand, optimizing the relative weight of groups of clinical attributes resulted in a substantial improvement of VTE risk prediction. In particular, patients classified as at risk with ML-RO-2 ( Figure 3C ) had a significantly lower 6-month VTEfree survival compared with patients classified as low risk.
DISCUSSION
The present study was designed to investigate the performance of ML as a novel methodological approach to derive a VTE risk classifier in chemotherapy-treated cancer outpatients. In the algorithm here presented, we applied a combined approach of kernel machines and RO of performance of binary classifiers, hypothesizing that this method would have found combination of attributes yielding the best classification performance of our predictors over a testing set. The predictive value of our learned models was also compared with the Khorana's risk assessment tool.
The results obtained demonstrated, for the first time to our knowledge, that this approach can be advantageous in VTE risk assessment and allowed us to draw some interesting considerations.
First, the analysis of clinical/biochemical variables identified several risk factors, not previously included in VTE risk models (i.e., blood lipids or ECOG-PS), as evidenced by attributes' weights (Table 3) . Moreover, ML models using all clinical attributes (Basic-ML-K, Basic-ML, and ML-ROs) showed better F-measures and LRs than generic models (pure KS and Khorana-ML), as verified on the training and, more importantly, on the testing set. Using additional clinical attributes is thus promising.
Second, ML-ROs, which optimize the relative importance of groups of clinical attributes, appeared extremely useful in selecting better VTE risk predictors. It is obvious that on the training set, F-measures of ML-ROs were better than Basic-ML as RO was performed on the training set. It is less obvious that ML-ROs generally outperformed Basic-MLs on the testing set in terms of F-measure.
Most importantly, best scoring models in terms of both F-measure and LRs were also clinically plausible, as demonstrated by the finding that blood lipids, BMI, and ECOG-PS retained the strongest weight both in ML-RO-3-K and in ML-RO-2 (Table 3 ). This is consistent with data showing that high-density lipoprotein cholesterol 32 and ECOG-PS 28, 30 might be good predictors of increased VTE risk in chemotherapy-treated cancer patients. Moreover, the ML-RO-2 model showed a weak association with tumor site and stage and with drugs, which is not surprising, since these variables have been previously related with increased VTE risk. 7, 11 Undeniably, advanced cancer, either locally (regional) or distant, 33 has been considered as a risk factor for VTE, and anticancer drugs may act as thrombotic triggers. 6, 34 One major criticism raised to KS is that it does not consider treatment-related risk of VTE, at a point that certain anticancer agents have been proposed to be used to implement KS. 11 Of course, we must acknowledge the low performance of both KS and ML-RO predictors in our model, either in terms of PPV or F-measures. This could be explained by the fact that this kind of data set is extremely unbalanced. Indeed, VTE occurred only in 8% of the cases (in line with the literature), which renders the application of ML models extremely difficult, consistent with Larrañ aga and others. 18 Previous studies in the general population showed better predictive performance, 21 but the test set used generally consisted of VTE cases paired to non-VTE controls. Our study cohort, instead, consisted of outpatients consecutively enrolled, in whom all VTE events were prospectively recorded during chemotherapy. Moreover, while in hospitalized patients cancer is connoted as one of the risk factors for VTE, 35 in an outpatient population, such as ours, the attribute ''cancer'' is expanded into several clinical attributes (i.e., site and stage or anticancer/supportive drugs) that portend different degrees of risk and might weight differently in the context of a ML algorithm.
There are, of course, some limitations to acknowledge. First, the model here reported was designed and validated on a data set that was not extracted from the EHR of single patients because of privacy restrictions in reference to identifiable individuals, as the Medical Oncology Unit stores EHRs under data protection legislation. These records, however, are highly customized into structured and nonstructured fields including demographics, medical and family history, vital signs, medications, diagnostics, and follow-up updating. Thus, all variables necessary for prediction are easily extractable from EHRs, once the model is validated for clinical use, as recently demonstrated by Lustig and others, 36 who implemented KS with EHRs extraction to readily stratify at-risk patients. Although glycemic profile and blood lipid pattern might not be always included in the prechemotherapy patient workout, we should take into consideration that these analytes are easy to perform and relatively inexpensive. This facilitates their inclusion in a validated clinical model with a negligible increase in health care costs.
Another limitation might reside in the fact that the study was monocentric. However, the primary aim of this study was not to present a new classifier that other centers can adopt but rather to propose the application of ML approach in VTE risk assessment models. Here, we demonstrate that the use of ML algorithms and RO models might be useful in developing local classifiers capable of improving the original KS while retaining other advantages (e.g., recalculation based on data advance over time) in a perspective of precision medicine. Presently, we are involved in the development of an operatorfriendly web interface, whose server component calculates VTE risk based on ML-RO-2 and returns to the client a binary information on risk (yes/no).
CONCLUSIONS
In conclusion, an ML approach might represent a suitable approach to VTE risk prediction by taking into consideration individual biological variability, environmental exposure, and lifestyle, in a context of precision medicine. This is particularly appealing in a big data scenario, in which clinical/biochemical attributes, routinely collected in EHRs, may be used to design new tools for clinical decision making. Indeed, the method we propose to find the optimal VTE predictors has the unquestionable advantages of selecting the best predictors on training data and to determine the relative weights between groups of clinical attributes. Furthermore, it demonstrates that other variables must be considered in VTE risk evaluation, thus strengthening the concept that data should not be considered singularly but in a more general association, as advocated by precision medicine.
This risk stratification approach well fits with others who identified the need of developing new guidelines or of identifying topics deserving further ad hoc clinical trials 37 and might help in filling the gap left by current guidelines concerning VTE prophylaxis.
Ongoing research involves 1) the use of other optimization methods such as simulated annealing and genetic algorithms and 2) the development of a web server interface using the proposed algorithm and its external validation by collaborating oncology wards. Nonetheless, the results here reported add further evidence to the rising idea that locally trained models may be of advantage over the classic scoring schemes, which, in time, can lose their prediction value and become less accurate.
